Skip to main content

IGMS

Stock
Health Care
Biotechnology

Performance overview

IGMS Price
Price Chart

Forward-looking statistics

Beta
1.61
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees235
Market cap$485.2M

Fundamentals

Enterprise value-$40.8M
Revenue$2.7M
Revenue per employee—
Profit margin0.00%
Debt to equity6298.14

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.27
Dividend per share—
Revenue per share$0.04
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$3M
Put-call ratio—

Macro factor sensitivity

Growth+10.0
Credit+3.7
Liquidity-5.4
Inflation+6.6
Commodities+4.8
Interest Rates-4.5

Valuation

Dividend yield0.00%
PEG Ratio-0.57
Price to sales30.53
P/E Ratio-0.57
Enterprise Value to Revenue-15.23
Price to book113.33

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.83 per share a year ago.

Zacks Investment Research (May 13, 2025)
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

On Tuesday, IGM Biosciences Inc. IGMS announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases.

Benzinga (October 1, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free